Strategies and lessons learned from a type 1 circulating vaccine-derived poliovirus (cVDPV) outbreak affecting adult population: Madagascar, 2020-2023.
Aug 2026· Vaccine· Vol 89, pp.
128987
· 0 citations· 16 references
Medicine
TL;DR
The cVDPV1 outbreak in Madagascar demonstrated the potential for significant adult involvement and high mortality in polio outbreaks, and highlighted the importance of inclusive vaccination strategies and tailored approaches in similar settings.
Abstract
INTRODUCTION
From 2020 to 2023, Madagascar experienced an outbreak of circulating vaccine-derived poliovirus type 1 (cVDPV1) that notably affected adults and was associated with high mortality among paralytic cases. This atypical epidemiological pattern required adapted surveillance approaches and tailored outbreak response strategies, including vaccination campaigns targeting adult populations.
Methods
We conducted a descriptive analysis of the cVDPV1 outbreak in Madagascar between September 2020 and September 2023. Epidemiological data on confirmed and polio-compatible cases were reviewed, including age distribution, clinical presentation, and outcomes. We also documented outbreak response strategies, particularly vaccination campaigns and operational innovations implemented to reach adult populations.
Results
A total of 54 confirmed cases of paralytic polio caused by cVDPV1 were reported during the study period, including two adults presenting with fever and paralysis. Between February 2022 and March 2023, 15 adult acute flaccid paralysis cases were classified as polio-compatible by the National Polio Eradication Committee due to missing (86%) or negative laboratory specimens. Mortality among these compatible adult cases was 56%. In response, Madagascar conducted vaccination campaigns using bivalent oral polio vaccine, targeting the entire population in four regions and children under 15 years in the rest of the country. Critical role of country leadership, strategic mobilization, and effective communication in driving success and influencing risk perception during the 2023 campaigns helped achieve high coverage among adults.
Conclusions
The cVDPV1 outbreak in Madagascar demonstrated the potential for significant adult involvement and high mortality in polio outbreaks. High vaccination coverage combined with targeted innovations and strong community engagement contributed to successful outbreak control. These findings highlight the importance of inclusive vaccination strategies and tailored approaches in similar settings.
The resurgence of WPV1 in polio-free regions in Afghanistan and Pakistan and the spread of cVDPVs challenge global polio eradication, highlighting the need for rapid detection, expanded nOPV2 use in areas with prolonged transmission, and sustained partner engagement and strategic resource allocation amid declining glob...
H. Whitmire, M. Z. Wadood, Ina G. Storm et al.· Archives of Public Health· 0 citations
BACKGROUND
Meningococcal meningitis remains a major public health challenge in Africa's meningitis belt despite the successful elimination of serogroup A epidemics following MenAfriVac introduction. Outbreaks caused by serogroups C, W, and X persist. NmCV-5, a pentavalent conjugate vaccine targeting serogroups A, C, W,...
Laura V Cooper, Médard Djedanem, Assan Abdoul Nasser et al.· Vaccine· 0 citations
Although this study focused on responses to A(H5N1) outbreaks, the findings are indicative of the nation's overall readiness for biological threats and prioritization of capacity building for infectious disease outbreaks is critical to prevent more widespread transmission.
Diane Meyer, Andreas Uhlig, Diné Butler et al.· American Journal of Public H...· 0 citations
Abstract Global polio eradication is challenged by persistent wild poliovirus type 1 (WPV1) transmission and outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2). The 2016 global withdrawal of the type 2 component from trivalent oral poliovirus vaccine (tOPV) created population immunity gaps, facilitatin...
Stéphane-Hans Bateyi Mustafa, Tambwe Patrick Rodrigue, Raha Zihindula Raoul et al.· Infection and Drug Resistanc...· 0 citations
Reported AEFIs following yellow fever vaccination were more frequent among adults aged ≥60 years, with a particularly marked increase in the oldest age groups, and vaccination decisions for older adults should be guided by individualized benefit–risk assessment rather than age alone.
Heriberto Vásquez-Serna, C. Jiménez-Canizales, C. A. Huertas-Caro et al.· Vaccines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.